SAMS Endorses the American Made Pharmaceuticals Act of 2022

WASHINGTON, D.C., April 5, 2022 – The Securing America’s Medicines and Supply (SAMS) coalition — a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States — today endorsed the introduction of the American Made Pharmaceuticals Act of 2022.

 “Global conflicts expose that we are overly reliant on foreign sources for life-saving drugs and treatments,” said David Sanders, SAMS Executive Director. “Our country needs more U.S. and ally-based capacity, from vaccines and generics to complex biologics and biosimilars. Senators Tina Smith and Tom Cotton are leading their colleagues by recognizing and rewarding pharmaceutical manufacturing here. Medicare, and other government programs, should recognize and reward high quality products made here with American workers. Together, government and industry can cure and secure the healthcare supply chain. This is why SAMS supports the American Made Pharmaceutical Act.”

This legislation tests a new tool — preferential treatment under the Medicare, Medicaid, and CHIP programs for biosimilars, generics and critical drugs in the United States – to encourage the return of pharmaceutical companies to the U.S.

About Securing America’s Medicines and Supply 

Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States. SAMS seeks to drive implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.